Proxygen GmbH
36 employees on LinkedIn · 1 known investors
Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.
Investors · 1
Frequently asked questions
- What does Proxygen GmbH do?
- Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.
- Who are Proxygen GmbH's investors?
- Proxygen GmbH's investors include Wlanholding.